Resource impact statement
No significant resource impact is anticipated
NICE has recommended venetoclax monotherapy, within its marketing authorisation, for treating chronic lymphocytic leukaemia in adults:
- with a 17p deletion or TP53 mutation and when a B‑cell receptor pathway inhibitor is unsuitable, or whose disease has progressed after a B‑cell receptor pathway inhibitor or
- without a 17p deletion or TP53 mutation, and whose disease has progressed after both chemo-immunotherapy and a B‑cell receptor pathway inhibitor.
It is recommended only if the company provides venetoclax according to the commercial arrangement (see section 2 of guidance).
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the population size is small. Venetoclax is currently available in the Cancer Drugs Fund and will transition to routine commissioning after publication of this guidance.
Venetoclax has a discount that is commercial in confidence. For enquiries about the patient access scheme please contact pricing@abbvie.com.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: